该行认为，此次公司高管以自有资金增持公司股权，体现了管理层对于公司A股IPO进展以及中长期战 略发展的信心。此前，公司于2025年9月15日在官方公众号发文，公司A股IPO启动会圆满举行，意味着 公司未来有望通过A股IPO上市进一步提升资本市场流动性。此外，公司正积极推进介入式脑机接口产 品的医疗器械注册流程，预计2026年底完成首例人体临床入组。 智通财经APP获悉，心玮医疗-B(06609)涨超11%，截至发稿，涨11.17%，报60.7港元，成交额764.81万 港元。 消息面上，2025年12月12日，心玮医疗-B公告，拟折价1.10%向张涵配售100万股内资股，净筹4325万 港元。中信建投指出，预计交易完成之后，将进一步增厚公司的流动现金储备，该笔现金预计在2028年 底前全部使用，用于在医疗器械行业的投资/并购，有望扩大公司产品组合，助力公司长期可持续增 长。 ...

资金面上，麦澜德上一交易日主力资金净流入959.18万元，近5日净流入4416.20万元。 融资融券数据显示，该股最新（12月31日）两融余额为1.15亿元，其中，融资余额为1.15亿元，较上一 个交易日增加147.02万元，增幅为1.30%；融券余额为37.13万元，较上一个交易日增加1.65万元，增幅 为4.65%。近10日两融余额合计增加699.46万元，增幅为6.46%，其间融资余额增长6.22%，融券余额增 长235.77%。 从机构评级来看，近一个月该股获1家机构买入评级。12月8日华源证券发布的研报给予公司买入评级。 1月5日盘中科创板股麦澜德涨停，截至09:46，股价报51.02元，成交2.48亿元，换手率13.57%，振幅 9.74%。 科创板个股中，截至发稿上涨的有493只，下跌的有101只，涨停的有翔宇医疗、麦澜德等，跌幅居前的 有铂力特、富吉瑞、有研粉材等，分别下跌9.88%、9.43%、6.31%。 （文章来源：证券时报网） ...

1月5日盘中科创板股翔宇医疗涨停，截至09:36，股价报72.60元，成交3.23亿元，换手率2.80%，振幅 4.13%。 科创板个股中，截至发稿上涨的有482只，下跌的有113只，涨幅居前的有翔宇医疗、麦澜德、博拓生物 等，分别上涨20.00%、17.12%、16.44%，跌幅居前的有富吉瑞、铂力特、有研粉材等，分别下跌 10.62%、10.42%、5.66%。 资金面上，翔宇医疗上一交易日主力资金净流入1421.81万元，近5日净流入6316.46万元。 融资融券数据显示，该股最新（12月31日）两融余额为1.95亿元，其中，融资余额为1.94亿元，较上一 个交易日减少17.85万元，降幅为0.09%；融券余额为38.12万元，较上一个交易日增加0.43万元，增幅为 1.15%。近10日两融余额合计增加2339.00万元，增幅为13.66%，其间融资余额增长13.65%，融券余额增 长19.73%。（数据宝） （文章来源：证券时报网） ...

A股2026年首个交易日，三大股指集合竞价集体高开，上证指数高开0.46%，深证成指高开0.8%，创业板指高开0.84%。截至发稿时，上证指数上涨 0.66%，深证成指上涨1.32%，创业板指上涨1.49%。 | NYMEX WTI原油 | ICE布油 | ICE轻质低硫原油 | | --- | --- | --- | | 57.48 | 60.98 | 57.00 | | +0.16 +0.28% | +0.23 +0.38% | -0.01 -0.02% | | INE原油 | INE低硫燃料油 | NYMEX天然气 | | 429.4 | 2932 | 3.459 | | -7.1 -1.63% | -24 -0.81% | -0.159 -4.39% | 三是科技股走强，半导体产业链和消费电子概念领涨，AI应用主线表现活跃。具体来看，半导体产业链中，存储芯片板块大涨，香农芯创（300475）、 江波龙（301308）等个股大涨。 盘面上，市场主要有以下几条主线走强： 一是新兴产业类主题赛道。脑机接口板块早盘大涨，倍益康、三博脑科（301293）等个股大涨。商业航天、可控核聚变等板块上涨。 消息面上，埃 ...

Core Insights - The Chinese open stapler market is experiencing a decline, with the market size decreasing from 15.3 billion yuan in 2020 due to the pandemic, and projected to reach 14.1 billion yuan in 2024, a year-on-year decrease of 2.1% [2] - The decline is attributed to the shift towards minimally invasive surgical techniques, with laparoscopic staplers becoming the mainstream due to their advantages such as less trauma and faster recovery [2] - Despite the decline, open staplers still hold irreplaceable value in grassroots medical settings and complex surgeries, indicating a potential stabilization in market size, although their market share is expected to continue decreasing [2] Industry Overview - Open staplers are primarily used in traditional open surgeries, offering advantages such as quick suturing, ease of use, single-use to prevent cross-infection, and fewer complications [3][4] - The types of open staplers include linear staplers, tubular digestive tract staplers, linear cutting staplers, anal staplers, purse-string staplers, curved cutting staplers, and skin staplers, each with specific applications [4] - The industry chain consists of upstream material suppliers, midstream manufacturers, and downstream consumers such as hospitals and clinics [6] Market Dynamics - The number of medical institutions in China is on the rise, projected to reach 1,093,600 by 2024, which will increase the demand for open staplers [8] - The competition in the open stapler market is shifting towards product upgrades and cost control as the market space contracts [10]

12月31日，山外山跌0.80%，成交额4207.31万元。两融数据显示，当日山外山获融资买入额620.50万 元，融资偿还715.94万元，融资净买入-95.44万元。截至12月31日，山外山融资融券余额合计9517.01万 元。 融资方面，山外山当日融资买入620.50万元。当前融资余额9486.18万元，占流通市值的1.98%，融资余 额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，山外山十大流通股东中，鹏华医药科技股票A（001230）位居第 四大流通股东，持股518.20万股，为新进股东。博时医疗保健混合A（050026）位居第六大流通股东， 持股325.70万股，持股数量较上期不变。 责任编辑：小浪快报 资料显示，重庆山外山血液净化技术股份有限公司位于重庆市两江新区慈济路1号，成立日期2001年3月 26日，上市日期2022年12月26日，公司主营业务涉及血液净化设备的研发、生产和销售。主营业务收入 构成为：血液净化设备66.12%，血液净化耗材23.89%，医疗服务8.31%，其他1.68%。 截至10月31日，山外山股东户数1.12万，较上期增加8.86%；人 ...

Group 1 - The core viewpoint of the news is that Dongxing Medical has experienced a decline in stock performance and financial metrics, indicating potential challenges in its business operations [1][2]. - On December 31, Dongxing Medical's stock fell by 0.94%, with a trading volume of 12.79 million yuan. The net financing buy was -204.70 thousand yuan, indicating more selling than buying in the financing market [1]. - As of December 31, the total balance of margin trading for Dongxing Medical was 79.95 million yuan, with a financing balance of 79.65 million yuan, accounting for 4.59% of the circulating market value, which is above the 50% percentile level over the past year [1]. Group 2 - As of December 19, the number of shareholders for Dongxing Medical was 9,304, a decrease of 2.90% from the previous period, while the average circulating shares per person increased by 2.99% to 7,325 shares [2]. - For the period from January to September 2025, Dongxing Medical reported a revenue of 284 million yuan, a year-on-year decrease of 10.21%, and a net profit attributable to shareholders of -53.20 million yuan, reflecting a significant decline of 181.13% [2]. - Since its A-share listing, Dongxing Medical has distributed a total of 169 million yuan in dividends [3].

Group 1 - The core business of the company involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - As of September 30, 2025, the company achieved a revenue of 808 million yuan, representing a year-on-year growth of 34.24%, and a net profit attributable to shareholders of 180 million yuan, with a growth of 43.87% [2] - The company's revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] Group 2 - As of December 31, 2025, the company's financing balance reached 1.30 billion yuan, with a net financing purchase of 136,100 yuan on that day [1] - The company has distributed a total of 228 million yuan in dividends since its A-share listing [3] - The number of shareholders increased by 16.36% to 7,971 as of September 30, 2025, while the average circulating shares per person decreased by 14.20% to 7,080 shares [2]

机构持仓方面，截止2025年9月30日，联影医疗十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股1903.56万股，相比上期减少298.09万股。易方达上证科创板50ETF（588080）位居第八大 流通股东，持股1787.43万股，相比上期减少259.56万股。华夏上证科创板50成份ETF（588000）位居第 九大流通股东，持股1745.84万股，相比上期减少908.62万股。华宝中证医疗ETF（512170）退出十大流 通股东之列。 责任编辑：小浪快报 资料显示，上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号，成立日期2011年3月21 日，上市日期2022年8月22日，公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为：销售医学影像诊断设备及放射治疗设备 81.29%，提供维修收入13.56%，其他(补充)4.68%，软件收入0.47%。 截至9月30日，联影医疗股东户数3.24万，较上期增加96.28%；人均流通股25444股，较上期减少 29.23%。2025年1月-9月，联影医疗实现营业收入88.59亿 ...

Core Viewpoint - Microelectrophysiology experienced a decline of 1.49% on December 31, with a trading volume of 71.91 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On December 31, the financing buy amount for Microelectrophysiology was 14.78 million yuan, while the financing repayment was 21.49 million yuan, resulting in a net financing outflow of 6.71 million yuan [1]. - As of December 31, the total financing and securities lending balance for Microelectrophysiology was 312 million yuan, with the financing balance accounting for 10.75% of the circulating market value, indicating a high level compared to the past year [1]. - The company had no shares repaid in securities lending on December 31, with 7,700 shares sold short, amounting to 178,300 yuan at the closing price, and a securities lending balance of 1.05 million yuan, also at a high level compared to the past year [1]. Business Performance - For the period from January to September 2025, Microelectrophysiology achieved an operating income of 336 million yuan, representing a year-on-year growth of 15.65%, while the net profit attributable to shareholders was 41.92 million yuan, showing a slight increase of 0.46% year-on-year [2]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Microelectrophysiology was 9,580, an increase of 9% from the previous period, while the average circulating shares per person decreased by 8.26% to 13,033 shares [2]. - The top circulating shareholders included Huatai-PineBridge Innovation Medical Mixed A as the largest shareholder with 4.73 million shares, an increase of 308,600 shares, while other significant shareholders saw varying changes in their holdings [3].